Tag: Epidiolex

GW Pharma Epidiolex FDA Decision Date Set for June 27th

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
- December 28th, 2017 at 7:25 am

GW Pharma Expects FDA Decision on Epidiolex in Mid-2018

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
- December 4th, 2017 at 7:42 am

GW Pharma Progresses Towards Epidiolex FDA Submission

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
- December 5th, 2016 at 7:39 am

GW Pharma Soars on Takeover Rumors

Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in...
- September 7th, 2016 at 3:47 pm